Life Sciences Tools & Services · Nasdaq

TECHBIO-TECHNE Corp

Last close
$72.80 -0.1%
52-week range
$43.20 to $72.88
Market cap
$11.4B
Next earnings
Not scheduled

Fiscal 2026 at a glance

Revenue
$1.22B
-0% vs FY25
Net income
$182M
+148% vs FY25
Free cash flow
$263M
+3% vs FY25
Net cash
$64.7M
Cash $265M, debt $200M

Stock price

+171% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 3 of 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
67.0x
39.6x130x
60th percentile, above its median of 61.4x
Price / sales
9.3x
6.7x20.7x
35th percentile, below its median of 10.1x
EV / EBITDA
32.8x
22.5x59.5x
38th percentile, below its median of 34.0x
Price / free cash flow
37.1x
29.5x69.2x
20th percentile, below its median of 47.1x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
67.0x
Earnings yield
1.5%
Price / sales
9.3x
Price / book
5.3x
Price / operating cash flow
33.9x
EV / EBITDA
32.8x
EV / sales
9.0x
Free cash flow yield
2.7%

Profitability

Gross margin
65.8%
Operating margin
19.6%
Net margin
14.0%
Return on equity
7.9%
Return on capital
8.4%

Growth per year

Revenue, 3 years
+2.2%
Revenue, 5 years
+5.5%
Revenue, 9 years
+8.9%
EPS, 3 years
-13.0%

Balance sheet

Cash and investments
$350M
Total debt
n/a
Net cash
$350M
Debt / equity
n/a
Current ratio
2.28x

n/a: No debt reported

Shares and dividend

Shares outstanding
157M
Share count, 5 years
-3.0%
Beta, 1 year
0.64
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
29.1%

n/a: No dividend

Ten years of the business

Last 40 quarters, fiscal 2017 to 2026 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $300M
RevenueNet income
Gross profitLatest quarter $197M
EBITDALatest quarter $60.3M
Margins66 / 12 / 9%
GrossOperatingNet
Earnings per shareLatest quarter $0.18
Cash flowLatest quarter $73.1M
OperatingCapexFree
Cash vs debtLatest quarter $350M
Cash and investmentsTotal debt
P/E historyNow 67.0x
P/E, median 61.4x dashed
P/S historyNow 9.3x
P/S, median 10.1x dashed

Where the revenue comes from

Instruments went from 10% to 9% of revenue in 3 years

Share of revenue by product line, fiscal 2023 to 2026, as reported in the 10-K.

ConsumablesInstrumentsServicesRoyalty
FY23
81%10%
$1.14B
FY24
80%9%9%
$1.16B
FY25
80%9%9%
$1.22B
FY26
81%9%
$1.22B
Fiscal 2026 by product line
Product lineRevenueSharevs FY25
Consumables$985M81.1%+1%
Instruments$111M9.1%-1%
Services$94.3M7.8%-15%
Royalty$25.0M2.1%+5%

Life Sciences Tools & Services peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
TMO Thermo Fisher Scientific Inc. $259B +8% 17.9%36.9x5.5x 88th percentile
A Agilent Technologies, Inc. $49.0B +9% 22.2%34.2x6.7x 64th percentile
WAT Waters Corp $45.2B +81% 4.7%198x8.1x 90th percentile
IQV Iqvia Holdings Inc. $43.7B +9% 12.8%32.2x2.5x 38th percentile
MTD Mettler Toledo International Inc/ $34.6B +7% n/a37.7x8.2x 58th percentile
TECH BIO-TECHNE Corp $11.4B +1% 19.6%67.0x9.3x 60th percentile

The company

Sector
Health Care
Industry
Life Sciences Tools & Services
Headquarters
Minneapolis, MN
Fiscal year ends
June

Around the numbers

What the rest of EdgeStacker knows about TECH.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 355 active funds. Crowd level: quiet.

Open the Smart money tab